Answers are grounded in this paper and cite their sources.
A 28-year-old Caucasian woman presented with erythematous macules, patches, and scaly plaques that were occasionally pruritic and painful. Areas affected were the axillae, breasts, and groin. The patient's breasts and thighs exhibited signs of striae formation, one of the features of Cushing's syndrome.1 Ten years earlier, subcorneal pustular dermatosis (SCPD) was diagnosed; however, she claimed that symptoms first appeared when she was 3 years old. Symptoms waxed and waned throughout her life but had begun to progressively worsen. Overall, she was well-adjusted, having lived with the dermatosis for her entire life; however, the location of the rash and the associated pruritus interfered with sexual intimacy, occasionally causing her to become depressed. She reported no other systemic symptoms other than mild, morning joint stiffness, and no comorbidities were detected. Family history was negative for dermatologic disease. At presentation, results from the complete blood cell count, serum protein electrophoresis, and urine protein electrophoresis were all within normal limits. There were no visible pustules on presentation, but there were subclinical pustules on biopsy, confirming the diagnosis of moderate to severe SCPD. Pathology analysis revealed subcorneal and intraepidermal vesiculopustule formation with abundant neutrophils and a dermal superficial perivascular inflammatory infiltrate (Figure). Immunoglobulin (Ig)A pemphigus was ruled out since direct immunofluorescence was negative for all immunoreactants, including IgA, IgG, IgM, C1q, C3, C4, and fibrinogen with albumin as a control. Figure FigureOpen in figure viewerPowerPoint Photomicrograph of subcorneal pustular dermatosis. A large pustule is seen beneath the stratum corneum. Arrow indicates neutrophils on epidermal surface (hematoxylin and eosin stain, original magnification ×20). Past therapy included numerous topical steroidal treatments in addition to nonsteroidal treatments such as calcipotriol. At presentation, the patient was taking oral dapsone (75 mg alternating with 100 mg/d). Dapsone has long been considered the treatment of choice for SCPD,2 but it had been ineffective at this dosage, and the patient had experienced 2 of its well-known side effects: hemolytic anemia and peripheral neuropathy.3 A test for glucose-6-phosphate dehydrogenase deficiency, which can cause hemolytic anemia, was done before dapsone therapy and results were negative. Treatment was initiated with tetracycline (1000 mg bid), nicotinamide (500 mg bid), and the nonsteroidal topical tacrolimus twice a day. Tetracycline was used because other inflammatory skin disorders, such as bullous pemphigoid, respond to the antibiotic with or without nicotinamide.4, 5 Tetracycline was employed for 3.5 months, but failed to significantly reduce the signs and symptoms of the patient's disease. Alternative therapy was sought by changing topical tacrolimus to topical calcipotriol twice a day and adding the topical steroid 0.05% halobetasol propionate cream on weekends and 0.005% fluticasone propionate ointment Monday through Friday. Oral colchicine (0.6 mg bid) was also added, which anecdotally has been reported to be successful in the treatment of SCPD.2, 6 Despite these multiple therapies, the results were discouraging. Although colchicine initially provided relief, a flare occurred approximately 3 months later. The patient's skin striae also worsened as a result of steroid use. She was switched to the nonsteroidal cream pimecrolimus and prescribed potassium iodide, which has been used successfully to treat certain erythematous dermatoses.7 Concern for her thyroid function while taking potassium iodide led to the discontinuation of this drug after approximately 2 months and the resumption of oral dapsone—at the higher dose of 125 mg daily. Topical 5% dapsone gel in a glycerin liquid and hydroxyethylcellulose base was also prescribed and made by a local compounding pharmacy. The patient's condition proved recalcitrant to these treatments as well as all previous therapies. Psoralen and long-wave UV radiation has been reported successful in treating SCPD resistant to dapsone and colchicine,8 but the patient's work schedule did not permit light therapy treatments. Resolving the dermatosis and the distress associated with the treatment failures posed a mounting dilemma. Some believe SCPD is a variation of pustular psoriasis.2 Because the biologic agent etanercept is approved for treating chronic, moderate to severe plaque psoriasis and because of its reported benefits in the treatment of a single case of pustular psoriasis,9 treatment with etanercept was proposed. The patient agreed, insurance approval was obtained, and treatment was begun with 25 mg of etanercept biweekly, administered subcutaneously, which at the time was the dosage approved by the US Food and Drug Administration (FDA) for psoriatic arthritis. Tacrolimus 0.1% ointment, as needed, was reinitiated, and dapsone was gradually tapered off over 2 months. Significant improvement was noted after 1 month of etanercept therapy at 25 mg biweekly. Three months after initiation, etanercept therapy resulted in an 80% improvement. After 5 months of etanercept therapy, the patient's skin condition was mostly clear. The patient's dose was increased from 25 mg biweekly to 50 mg biweekly after the label indication for plaque psoriasis was approved by the FDA. After the dose increase, the patient no longer needed tacrolimus ointment or any medication other than etanercept for the SCPD. After 3 months at the higher dose, she was close to 100% clear of her dermatosis, and her improvement was sustained for an additional 3 months. Subsequently, the patient moved out of state and was lost to follow-up. Before leaving, she had been instructed to gradually taper her dose by increasing the intervals between doses (ie, injecting 50 mg every 5 days for 1 month, then 50 mg every 6 days for 1 month until reaching a maintenance dose of 50 mg once weekly). The patient's condition was monitored with comprehensive metabolic panels throughout therapy. The patient did not experience any injection site reactions, infections, organ dysfunction, or other adverse events during treatment with etanercept. An almost complete resolution of the patient's symptoms and clinical lesions associated with SCPD was noted within 3 months of the dose increase from 25 mg biweekly to 50 mg biweekly etanercept and was sustained at the time the patient relocated approximately 11 months after etanercept treatment had begun.
No takes yet. Share an insight, caveat, or question.
Monica K. Bedi (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: